Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) today announced the completion of enrollment for the US Phase II trial of its cholesterol-lowering compound, FM-VP4. To date, there have not been any significant safety issues or concerns raised during the trial's progress. The primary efficacy objective of this trial is to determine the effect of two doses of FM-VP4, 450mg and 900mg, given for 12 weeks, compared to placebo, on low density lipoprotein-cholesterol (LDL-C). The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at Week 12. The trial is expected to be completed by the end of the third quarter of 2006 with topline results anticipated to be released by year-end.
